Efavirenz (Sustiva) receives FDA approval. Food and Drug Administration.
D000328:Adult; D000480:Alkynes; D048588:Benzoxazines; D002648:Child; D002675:Child, Preschool; D003521:Cyclopropanes; D017277:Drug Approval; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D015507:Drugs, Investigational; D015658:HIV Infections / Q000188:drug therapy*; D006297:Health Services Accessibility; D006801:Humans; D010078:Oxazines / Q000009:adverse effects / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D014486:United States Food and Drug Administration
D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D015507:Drugs, Investigational; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; C098320:efavirenz